S. Gargiulo

Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer

E. Scarpi, V. Conteduca, B. Vincenzi, 2022, Scientific Reports.

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide

E. Scarpi, V. Conteduca, U. de Giorgi, 2020, Frontiers in Oncology.

Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer

V. Conteduca, U. de Giorgi, G. Schepisi, 2020, Expert opinion on pharmacotherapy.

Transesophageal echocardiography through a non-invasive ventilation helmet.

T. Iovino, A. Pisano, S. Manduca, 2013, Journal of cardiothoracic and vascular anesthesia.

The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment

V. Conteduca, U. de Giorgi, G. Schepisi, 2019, Cancers.

Plasma Androgen Receptor in Prostate Cancer

M. Pulvirenti, V. Conteduca, U. de Giorgi, 2019, Cancers.